Biocytogen Pharmaceuticals' 2025 Profit Surges as Revenue Rises 41%

MT Newswires Live03-27

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) booked 173.2 million yuan in attributable profit for 2025, rising from 33.5 million yuan in 2024, according to a Hong Kong bourse filing Thursday.

Shares of the pharmaceutical firm gained nearly 9% in afternoon trade Friday.

Earnings per share were 0.43 yuan, compared with 0.08 yuan in the prior year.

Revenue rose 41% year on year to 1.38 billion yuan, figures showed.

Meanwhile, in a separate announcement, the firm said its partner NEOK Bio received U.S. Food and Drug Administration approval to begin human trials of NEOK002.

The therapy was developed using Biocytogen's RenLite platform and will be studied as a treatment for advanced solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622981768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 13:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622981768","market":"us","top_or_hot":-1,"title":"Biocytogen Pharmaceuticals' 2025 Profit Surges as Revenue Rises 41%","media":"MT Newswires Live","content":"<html><body><p> Biocytogen Pharmaceuticals (Beijing) (HKG:2315) booked 173.2 million yuan in attributable profit for 2025, rising from 33.5 million yuan in 2024, according to a Hong Kong bourse filing Thursday.</p><p>Shares of the pharmaceutical firm gained nearly 9% in afternoon trade Friday.</p><p>Earnings per share were 0.43 yuan, compared with 0.08 yuan in the prior year.</p><p>Revenue rose 41% year on year to 1.38 billion yuan, figures showed.</p><p>Meanwhile, in a separate announcement, the firm said its partner NEOK Bio received U.S. Food and Drug Administration approval to begin human trials of NEOK002.</p><p>The therapy was developed using Biocytogen's RenLite platform and will be studied as a treatment for advanced solid tumors.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen Pharmaceuticals' 2025 Profit Surges as Revenue Rises 41%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen Pharmaceuticals' 2025 Profit Surges as Revenue Rises 41%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-27 13:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biocytogen Pharmaceuticals (Beijing) (HKG:2315) booked 173.2 million yuan in attributable profit for 2025, rising from 33.5 million yuan in 2024, according to a Hong Kong bourse filing Thursday.</p><p>Shares of the pharmaceutical firm gained nearly 9% in afternoon trade Friday.</p><p>Earnings per share were 0.43 yuan, compared with 0.08 yuan in the prior year.</p><p>Revenue rose 41% year on year to 1.38 billion yuan, figures showed.</p><p>Meanwhile, in a separate announcement, the firm said its partner NEOK Bio received U.S. Food and Drug Administration approval to begin human trials of NEOK002.</p><p>The therapy was developed using Biocytogen's RenLite platform and will be studied as a treatment for advanced solid tumors.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2622981768","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622981768","pubTimestamp":1774590154,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biocytogen Pharmaceuticals   booked 173.2 million yuan in attributable profit for 2025, rising from 33.5 million yuan in 2024, according to a Hong Kong bourse filing Thursday.Shares of the pharmaceutical firm gained nearly 9% in afternoon trade Friday.Earnings per share were 0.43 yuan, compared with 0.08 yuan in the prior year.Revenue rose 41% year on year to 1.38 billion yuan, figures showed.Meanwhile, in a separate announcement, the firm said its partner NEOK Bio received U.S. Food and Drug Administration approval to begin human trials of NEOK002.The therapy was developed using Biocytogen's RenLite platform and will be studied as a treatment for advanced solid tumors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02315":"百奥赛图-B"},"translate_title":"百奥赛图制药2025年利润飙升，营收增长41%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"Biocytogen Pharmaceuticals (Beijing) (HKG:2315) booked 173.2 million yuan in attributable profit for 2025, rising from 33.5 million yuan in 2024, according to a Hong Kong bourse filing Thursday.Shares of the pharmaceutical firm gained nearly 9% in afternoon trade Friday.Earnings per share were 0.43 yuan, compared with 0.08 yuan in the prior year.Revenue rose 41% year on year to 1.38 billion yuan, figures showed.Meanwhile, in a separate announcement, the firm said its partner NEOK Bio received U.S. Food and Drug Administration approval to begin human trials of NEOK002.The therapy was developed using Biocytogen's RenLite platform and will be studied as a treatment for advanced solid tumors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622981768","isCrawlerRequest":true}